One week af­ter Take­da walked away, Finch faces sec­ond round of lay­offs, pipeline prun­ing

Finch may be an inch un­der­ground at this point.

Somerville, MA-based Finch Ther­a­peu­tics has had a rough year, start­ing with the FDA slap­ping a clin­i­cal hold on its late-stage C. dif­fi­cile treat­ment in March. While that hold was lift­ed at the end of April, it had al­ready tak­en its toll, with Finch lay­ing off 37 of its work­ers and cut­ting its he­pati­tis B pro­gram in the in­ter­im.

Then, last week, Take­da end­ed its five-year al­liance with the biotech, giv­ing back glob­al rights to two pre­clin­i­cal pro­grams in ul­cer­a­tive col­i­tis and Crohn’s dis­ease. In re­ac­tion to that, Finch is lay­ing off an ad­di­tion­al 50 em­ploy­ees, about an­oth­er third of its work­force, ac­cord­ing to an SEC fil­ing this morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER